The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma
Open accessAbstract
Summ a r yAntigen-driven selection has been implicated in the pathogenesis of monoclonal gammopathies.Patients with Gaucher's disease have an increased risk of monoclonal gammopathies.Here we show that the clonal immunoglobulin in patients with Gaucher's disease and in mouse models of Gaucher's disease-associated gammopathy is reactive against lyso-glucosylceramide (LGL1), which is markedly elevated in these patients and mice.Clonal immunoglobulin in 33% of sporadic human monoclonal gammopathies is also specific for the lysolipids LGL1 and lysophosphatidylcholine (LPC).Substrate reduction ameliorates Gaucher's disease-associated gammopathy in mice.Thus, longterm immune activation by lysolipids may underlie both Gaucher's disease-associated gammopathies and some sporadic monoclonal gammopathies.M ultiple myeloma and monoclonal gammopathy of undetermined significance (MGUS) are characterized by clonal expansion of transformed plasma cells. 1 Analyses of immunoglobulin genes in tumor cells have provided evidence of antigen-driven selection, with restricted heavy-chain variableregion use and highly hypermutated immunoglobulin heavy-and light-chain genes. [2][3]][4][5][6] However, the antigens underlying the origins of most MGUS and myeloma clones remain unknown.Hyperphosphorylated modification of stomatin (EPB72)-like 2 protein (STOML2, which is identical to paratarg-7) due to the inactivation of protein phosphatase 2A was identified as a target of certain paraproteins and an inherited risk factor for the development of gammopathies.[7][8][9] A recent study identified sumoylated heat-shock protein 90 as another inherited risk factor for plasma-cell dyscrasia.10 However, there remains a need to identify the antigenic origins of MGUS and myeloma that may be amenable to targeted prevention.Lipids (such as pristane) were implicated in the earliest models of murine plasmacytoma, 11 and lipid disorders such as Gaucher's disease and obesity are associated with an increased risk of myeloma.12,13 The risk of myeloma is markedly higher among patients with Gaucher's disease, in whom myeloma is now emerging as a leading cause of cancer-related death, than in the general population.13 Glucocerebrosidase deficiency in Gaucher's disease leads to increases in the level of LGL1.14 Recently, we identified a subset of human and murine LGL1-specific CD1d-restricted type 2 natural killer T cells that constitutively expressed markers of follicular helper T cells and helped in the differentiation of lipid-reactive plasma cells.15 In an earlier study, we found an elevation of type 2 natural killer T cells against another bioactive lysolipid, LPC, in myeloma.16 These studies led us to test whether the clonal immunoglobulin in Gaucher's disease-associated myeloma and sporadic myeloma was reactive against LGL1 and LPC. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, several studies have supported the idea that the B-cells from which MM originate, experience a prolonged/chronic stimulation in the GC.15,40,41,70,71”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This idea of chronic stimulation or B-cells re-entering has found robust evidence in the Gaucher disease where the chronic stimulation of B-cells against lyso-glucosylceramide (LGL1) promotes the development of MGUS with clonal immunoglobulin specific for LGL1.40,41”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, it has also been demonstrated that patients exposed to certain agents (e.g. Agent Orange in Vietnam veterans, pesticides in agricultural worker, or 9/11 World Trade Center dust in first responders) or those suffering from specific conditions (such as HIV or Gaucher) have a higher prevalence of these clonal populations. 37-39 40,41 42”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Pietiläinen, K. H., Sysi‐Aho, M., Rissanen, A., Seppänen‐Laakso, T., Yki‐Järvinen, H., Kaprio, J. A., & Orešič, M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000218 · Cited by 418
Bakkus, M. H. C., Heirman, C., Riet, I. V., Camp, B. V., & Thielemans, K. (1992) · Blood · doi:10.1182/blood.v80.9.2326.2326 · Cited by 315
Dekker, N., van Dussen, L., Hollak, C., Overkleeft, H., Scheij, S., Ghauharali, K., van Breemen, M. V., Ferraz, M. J., Groener, J., Maas, M., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352971 · Cited by 277
Self-citationMistry, P. K., Liu, J., Yang, M., Nottoli, T., McGrath, J. M., Jain, D., Zhang, K., Keutzer, J. M., Chuang, W., Mehal, W. Z., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003308107 · Cited by 244
Self-citationInduction of Plasma Cell Tumours in BALB/c Mice with 2,6,10,14-Tetramethylpentadecane (Pristane)
ANDERSON, P. N., & Potter, M. (1969) · Nature · doi:10.1038/222994a0 · Cited by 192
Landgren, O., Rajkumar, S. V., Pfeiffer, R. M., Kyle, R. A., Katzmann, J. A., Dispenzieri, A. A., Cai, Q., Goldin, L. R., Caporaso, N. E., Fraumeni, J. F., et al. (2010) · Blood · doi:10.1182/blood-2010-01-262394 · Cited by 165
Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1
Mistry, P. K., Lukina, E., Turkia, H. B., Amato, D., Baris, H. N., Dasouki, M., Ghosn, M. G., Mehta, A. B., Packman, S., Pastores, G. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.459 · Cited by 156
Self-citationInflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer
Chang, D., Deng, H., Matthews, P., Krasovsky, J., Ragupathi, G., Špíšek, R., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2008) · Blood · doi:10.1182/blood-2008-04-149831 · Cited by 143
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 202
Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients
Bosseboeuf, A., Seillier, C., Mennesson, N., Allain‐Maillet, S., Fourny, M., Tallet, A., Piver, É., Lehours, P., Mégraud, F., Berthelot, L., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00854 · Cited by 17
Petrusca, D. N., Lee, K. P., & Galson, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925807 · Cited by 16
The chitinases as biomarkers in immune-mediate diseases
Francesco, A. M. D., Verrecchia, E., Manna, S., Urbani, A., & Manna, R. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0767 · Cited by 16
Saade, C., & Ghobrial, I. M. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104268 · Cited by 15
Trivedi, V. S., Magnusen, A. F., Rani, R., Marsili, L., Slavotinek, A. M., Prows, D. R., Hopkin, R. J., McKay, M. A., & Pandey, M. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214340 · Cited by 15
Lysosomal Storage Disorders and Malignancy
Pastores, G. M., & Hughes, D. A. (2017) · Diseases · doi:10.3390/diseases5010008 · Cited by 15
Basiri, M., Ghaffari, M. E., Ruan, J., Murugesan, V., Kleytman, N., Belinsky, G. S., Akhavan, A., Lischuk, A. W., Guo, L., Klinger, K. W., et al. (2023) · eLife · doi:10.7554/elife.87537 · Cited by 14
Self-citationRodríguez-García, A., Linares, M., Morales, M. L., Allain‐Maillet, S., Mennesson, N., Sánchez, R., Alonso, R., Leivas, A., Pérez‐Rivilla, A., Bigot‐Corbel, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.797209 · Cited by 14
Morelli, E., Ribeiro, C. F., Rodrigues, S. D., Gao, C., Socciarelli, F., Maisano, D., Favasuli, V. K., Liu, N., Todoerti, K., Chakraborty, C., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2000 · Cited by 14
Saposin C is a frequent target of paraproteins in Gaucher disease‐associated MGUS/multiple myeloma
Preuss, K., Hollak, C. E. M., Fadle, N., van Oers, M. H. J., Regitz, E., & Pfreundschuh, M. G. (2018) · British Journal of Haematology · doi:10.1111/bjh.15659 · Cited by 13
Harb, J., Mennesson, N., Lepetit, C., Fourny, M., Louvois, M., Bosseboeuf, A., Allain‐Maillet, S., Decaux, O., Moreau, C., Tallet, A., et al. (2021) · Cells · doi:10.3390/cells10020438 · Cited by 13
Prevalence of Cancer in Acid Sphingomyelinase Deficiency
Mauhin, W., Levade, T., Vanier, M. T., Froissart, R., & Lidove, O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215029 · Cited by 13
Inhibitors of Glucosylceramide Synthase
Shayman, J. A., Hinkovska‐Galcheva, V., & Shu, L. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-2910-9_20 · Cited by 13
Decreased Activity of Blood Acid Sphingomyelinase in the Course of Multiple Myeloma
Wątek, M., Piktel, E., Barankiewicz, J., Sierlecka, E., Kościołek-Zgódka, S., Chabowska, A. M., Suprewicz, Ł., Wolak, P., Durnaś, B., Bucki, R., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236048 · Cited by 12
Immune-Pathogenesis of Myeloma
Dhodapkar, M. V. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.011 · Cited by 12
Self-citationPotential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer
Dubot, P., Astudillo, L. M., Therville, N., Carrié, L., Pettazzoni, M., Cheillan, D., Stirnemann, J., Levade, T., Andrieu‐Abadie, N., & Sabourdy, F. (2022) · Cancers · doi:10.3390/cancers14194858 · Cited by 11
Jasiński, M., Biliński, J., & Basak, G. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.853540 · Cited by 12
Sahasrabudhe, S. A., Terluk, M. R., Rudser, K. D., Cloyd, J. C., & Kartha, R. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169189 · Cited by 11
The molecular biology of multiple myeloma
Chng, W. J., & Bergsagel, P. L. (2019) · Wiley eBooks · doi:10.1002/9781119252863.ch10 · Cited by 9
Editorial: The Role of Microorganisms in Multiple Myeloma
Linares, M. J. P., & Hermouet, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.960829 · Cited by 9
Evolution of Multiple Myeloma from a Genomic Perspective
Maura, F., Samur, M., & Munshi, N. (2026) · Blood · doi:10.1182/blood.2024026313 · Cited by 8
Immune alterations in myeloma evolution and outcomes: quo vadis?
Dhodapkar, M. V., & Paiva, B. (2025) · Blood · doi:10.1182/blood.2024026227 · Cited by 8
Self-citationGlucosylsphingosine (Lyso-Gb1): An Update on Its Use as a Biomarker in Gaucher Disease
Carubbi, F., Linari, S., & Spada, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041705 · Cited by 8
Rodríguez-García, A., Mennesson, N., Hernández, G., Morales, M. L., Garderet, L., Bouchereau, L., Allain‐Maillet, S., Piver, É., Alvarez, I. M., Ruiz, D. R., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283096 · Cited by 8
Aerts, J. M. F. G., & Cox, T. M. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.10.030 · Cited by 8
Abell, K. B., Chadwell, S. E., Burrow, T. A., Becker, A. P. P., Bailey, L. A., Steele, P. E., Zhang, X., Islas‐Ohlmayer, M., Bittencourt, R., Schwartz, I. V. D., et al. (2020) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31870 · Cited by 8
Taguchi, K., Moriyama, A., Kodama, G., Nakayama, Y., & Fukami, K. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7623 · Cited by 8
Dhodapkar, M. V., Sexton, R., Hoering, A., van Rhee, F., Barlogie, B., & Orlowski, R. Z. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2119 · Cited by 8
Self-citationGiuffrida, G., Markovic, U., Condorelli, A., Duminuco, A., Calafiore, V., Conticello, C., Romano, A., Grasso, S., Riccobene, C., Ragusa, M. T. V., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14105 · Cited by 7
Verma, K. P., Steuer, R. Z., & Edwards, C. V. (2023) · Hemato · doi:10.3390/hemato4040027 · Cited by 7
Adly, A. A. M., Ismail, E. A. R., Ibrahim, F. A., Atef, M., Sayed, K. A. E., & Aly, N. H. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12792 · Cited by 7
A bone paradigm challenging the standard model of myeloma oncogenesis
Capp, J., & Bataille, R. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103640 · Cited by 8
Regression of smoldering myeloma with treatment of Gaucher disease
Barley, K. M., Parekh, A., Salam, S. P., Mendu, D. R., Shukla, R. P., Vatti, D., Verina, D., Stauffer, C., Salib, C., Jamal, S. M. E., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012304 · Cited by 7
Pathogenese des Multiplen Myeloms
Rasche, L., & Weinhold, N. (2018) · Der Internist · doi:10.1007/s00108-018-0529-8 · Cited by 8
A 30-Year-Old Carrier of Gaucher Disease with Multiple Myeloma
Chadha, J. S., Sahai, T., Schwimmer, J. A., & Shani, D. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/6469196 · Cited by 7
Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients
Malinová, V., Poupětová, H., Řeboun, M., Dvořáková, L., Mazurová, S., Švandová, I., Murgašová, L., Kasper, D. C., & Magner, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914440 · Cited by 6
Deciphering metabolic shifts in Gaucher disease type 1: a multi-omics study
Ducatez, F., Berger, M. G., Pilon, C., Plichet, T., Lesueur, C., Berger, J., Belmatoug, N., Marret, S., Bekri, S., & Tebani, A. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02512-x · Cited by 6
Wilke, M. V. M. B., Iop, G. D., Faqueti, L. G., da Silva, L. A. L., Kubaski, F., Poswar, F. D. O., Michelin‐Tirelli, K., Randon, D. N., Borelli, W. V., Giugliani, R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052870 · Cited by 6
Limgala, R. P., Jani, C., Ioanou, C., Alpan, O., & Göker-Alpan, Ö. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.10.015 · Cited by 6
Multiple myeloma occurring in a case of Niemann‐Pick disease Type B: A pathophysiological link?
Portier, E., Talbot, A., Nguyen, Y., Royer, B., Pettazzoni, M., Salah, I. B., Trichet, C., Vercellino, L., Arnulf, B., & Belmatoug, N. (2022) · British Journal of Haematology · doi:10.1111/bjh.18050 · Cited by 6
The Ins and Outs of Endosteal Niche Disruption in the Bone Marrow: Relevance for Myeloma Oncogenesis
Capp, J., & Bataille, R. (2023) · Biology · doi:10.3390/biology12070990 · Cited by 6
Dimitriou, E., Paschali, E., Kanariou, M. G., & Michelakakis, H. (2019) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2019.100477 · Cited by 6
Vanier, M. T., Caillaud, C., & Levade, T. (2022) · Springer eBooks · doi:10.1007/978-3-662-63123-2_40 · Cited by 6
Aerts, J. M. F. G., Ferraz, M. J., Mirzaian, M., Gaspar, P., Oussoren, S. V., Wisse, P., Kuo, C. J., Lelieveld, L. T., Kytidou, K., Hazeu, M., et al. (2017) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0027592 · Cited by 6
Fernandez, N., Perumal, D., Rahman, A. H., Kim‐Schulze, S., Yesil, J., Auclair, D., Adams, H., Parekh, S. S., Gnjatic, S., & Cho, H. J. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.07.001 · Cited by 5
Role of Natural Killer T (NKT) Cells in Myeloma Biology and Therapy
Dhodapkar, M. V. (2023) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2023048380 · Cited by 5
Self-citationRare but important haematological conditions: Gaucher disease
Hughes, D. A. (2017) · Medicine · doi:10.1016/j.mpmed.2017.01.008 · Cited by 5
Multiple myeloma treatment: one bridge closer
Lucca, L. E. (2023) · Blood · doi:10.1182/blood.2023022470 · Cited by 5
Surowiec, P., Piątkowska‐Jakubas, B., Pawliński, Ł., Gałązka, K., Sacha, T., & Kieć‐Wilk, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175518 · Cited by 4
Choi, S., Kim, E., Jung, J., Park, S., Min, C., & Han, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-52720-1 · Cited by 4
Effect of adipose tissue on the development of multiple myeloma
Stanisławowski, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10174-8 · Cited by 4
Classifying the additional morbidities of Gaucher disease
Langeveld, M., Elstein, D., Szer, J., Hollak, C. E. M., & Zimran, A. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.12.006 · Cited by 4
Manifestations pulmonaires des maladies héréditaires du métabolisme
Mauhin, W., Brassier, A., London, J., Subran, B., Zeggane, A., Besset, Q., Jammal, C. E., Montardi, C., Mellot, C., Strauss, C., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.09.002 · Cited by 4
Screening for Gaucher disease among patients with plasma cell dyscrasias
Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Fotiou, D., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., Kastritis, E., Dimopoulos, M. A., & Terpos, E. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1672059 · Cited by 4
Terpos, E., & Gavriatopoulou, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65375-8 · Cited by 4
Kumar, M., & Feldman, R. A. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddaf166 · Cited by 4
Gaucher disease: the hematologist’s perspective of a multisystemic disorder
Costa, A., Mulas, O., & Caocci, G. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06977-3 · Cited by 3
Identification of the Lipid Antigens Recognized by rHIgM22, a Remyelination-Promoting Antibody
Grassi, S., Cabitta, L., Prioni, S., Mauri, L., Ciampa, M. G., Yokoyama, N., Iwabuchi, K., Zorina, Y., & Prinetti, A. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03859-2 · Cited by 3
Multiple Myeloma Associated with Dermatomyositis: A Short Report and Mini-Review
Serajul, I. M., & Pavel, K. (2018) · International Journal of Blood Research and Disorders · doi:10.23937/2469-5696/1410029 · Cited by 3
Papoutselis, M. K., & Spanoudakis, E. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.006 · Cited by 3
Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease
Liu, Y., Zhao, X., Jian, J., Hasan, S., & Liu, C.-J. (2023) · BioScience Trends · doi:10.5582/bst.2023.01022 · Cited by 3
Hermouet, S., Bigot‐Corbel, E., & Harb, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1253363 · Cited by 3
Exploring the role of viral hepatitis in plasma cell disorders
O’Donnell, E. (2023) · Haematologica · doi:10.3324/haematol.2023.283461 · Cited by 3
Hermouet, S., Mennesson, N., Allain‐Maillet, S., Bigot‐Corbel, E., Ólafsson, A., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., Sigurðardóttir, M. S., Þorsteinsdóttir, I., et al. (2024) · HemaSphere · doi:10.1002/hem3.70053 · Cited by 2
Istaiti, M., Dinur, T., Paltiel, O., SILVERMAN, B. G., Revel‐Vilk, S., & Zimran, A. (2025) · Internal Medicine Journal · doi:10.1111/imj.70221 · Cited by 2
Harb, J., Wilson, B. S., & Hermouet, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01761 · Cited by 2
Morè, S., Federici, I., Bossi, A., Rupoli, S., Morsia, E., Manieri, V. M., Olivieri, A., Petrucci, M. T., Fazio, F., Lisi, C., et al. (2025) · HemaSphere · doi:10.1002/hem3.70079 · Cited by 1
Multiple myeloma presenting with retroperitoneal fibrosis and elevated IgG4
Kayamori, K., Shono, K., Onoda, M., & Yokota, A. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-03999-x · Cited by 1
MAGa: Monoclonal Autoimmune Gammopathies
Torres, S., Wheeler, S. E., & Shurin, M. R. (2026) · Cancers · doi:10.3390/cancers18111770 · Cited by 1
Cumulative Antigen Suppression Reduces Clonal Plasma Cell Evolution in Gaucher Disease
Ain, N. U., Bar, N., Guo, L., Klinger, K., Gupta, P., Rahman, A. U., Yang, R., Deng, Y., Neparidze, N., Nair, S., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70407 · Cited by 1
Self-citationUnraveling the syndrome of age-associated diseases: Common pathways and novel therapeutic strategies
Mertelsmann, R. H., Faletti, L. E., & Zirlik, K. (2019) · Journal of Science Humanities and Arts - JOSHA · doi:10.17160/josha.6.2.539 · Cited by 1
Krishnan, A. Y., Nathwani, N., Amanam, I. U., & Gupta, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_5 · Cited by 1
Research Progress on Pathogenesis, Diagnosis and Treatment of Bone Damage in Gaucher Disease
步, 晓. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134802 · Cited by 1
Leng, H., Zhang, H., Li, L., Zhang, S., Wang, Y., Ersek, A., Morris, E. V., Sezgin, E., Lee, Y., Li, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.05.429906 · Cited by 1
Rôle des sphingolipides dans la cancérogenèse : l'exemple de la maladie de Gaucher
Astudillo, L. M. (2016) · theses.fr (ABES) · doi:10.70675/fa7a5078z1170z48a0z81a7z05c9d8e7a135 · Cited by 1
Once again, rare diseases provide a spotlight
Lal, T. R., Borger, D. K., & Sidransky, E. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.03.002
Ventura‐Aguiar, P., Cibeira, M. T., Martinez, A., Cuatrecasas, M., Aymerich, M., Ferrer, J., Bladé, J., Diekmann, F., & Ricart, M. J. (2019) · Case Reports in Nephrology · doi:10.1155/2019/2818074
A case of bony lytic lesions in a patient with Gaucher disease
McGinnis, E., & Razavi, H. M. (2019) · Clinical Case Reports · doi:10.1002/ccr3.2329
Zirlik, K., & Mertelsmann, R. H. (2019) · Journal of Science Humanities and Arts - JOSHA · doi:10.17160/josha.6.8.591
Manifestaciones osteoarticulares de las esfingolipidosis en adultos
Chalès, G., Guggenbuhl, P., Cador-Rousseau, B., Cathelineau, C., & Guillin, R. (2020) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(20)44332-1
Oszukańcza sprawozdawczość finansowa wobec teorii kontraktów i teorii agencji
Wójtowicz, P. (2009) · Zeszyty Naukowe / Akademia Ekonomiczna w Krakowie
Faculty Opinions recommendation of Sphingolipid metabolism in cancer signalling and therapy.
Loughran, T. P., & Tan, S. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732125735.793546487
Deegan, P. B., & Cox, T. M. (2020) · doi:10.1093/med/9780198746690.003.0235
Rare but important haematological conditions: Gaucher disease
Hughes, D. A., & Moreno-Martínez, D. (2021) · Medicine · doi:10.1016/j.mpmed.2021.01.014
Yee, A. J., Hideshima, T., Raje, N. S., & Anderson, K. C. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122.pub2
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
Maclachlan, K. H., & Lesokhin, A. M. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.014
Cox, T. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00282-0 · Cited by 1
Monoclonal Gammopathies with Miscellaneous Associations
Pioltelli, P. E., Atkinson, T. P., Mattar, M., Edrees, A., Ahmed, H. M. A., Laymouna, A. H., Abdel‐Halim, M. R. E., & Ragab, G. (2022) · Springer eBooks · doi:10.1007/978-3-031-10131-1_21
Thurner, L., & Kessel, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18566-3.00031-1
Maura, F., Landgren, O., & Morgan, G. J. (2023) · doi:10.1158/1078-0432.c.6530273
Maura, F., Landgren, O., & Morgan, G. J. (2023) · doi:10.1158/1078-0432.c.6530273.v1
Muradashvili, T., Yu, M., Browning, S. L., Bar, N., Gorshein, E., Parker, T. L., & Neparidze, N. (2024) · Leukemia · doi:10.1038/s41375-024-02380-x
Terpos, E., & Ntanasis‐Stathopoulos, I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00169-2
Inflammatory Factors and Immune Cells in Relation to Multiple Myeloma
Huang, M., Zeng, Q., Chen, D., Yang, C., Yang, Y., Zhou, M., Zhang, F.-L., Bian, Q.-H., & Yang, X. (2025) · Acta Haematologica · doi:10.1159/000543429
Rare biochemical & genetic conditions: clues for broader mechanistic insights
Mentis, A. A., & Dalamaga, Μ. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05652-6
Liver involvement in Gaucher disease in children: A literature review and clinical observations
Васильевна, В. Г., Movsisyan, G. B., Потапов, А. С., Хавкин, А. И., Nikitin, A. V., Андреевна, С. Т., Morozova, E. A., & Rogozhina, V. V. (2025) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro20251402178
The Role of Glycosphingolipids in Autoimmune Manifestations and Myeloma in Gaucher DiseasePreprint
Pavlova, E., Archer, J., Ferraz, M. J., Aerts, J. M. F. G., & Cox, T. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.28.666118
Monoclonal gammopathies and their management in Gaucher disease type 1
Lorber, J., & Rosenbloom, B. E. (2025) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.30
Fattahi, N., Ruan, J., Belinsky, G. S., Xing, S., Mistry, P. K., & Nair, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411915
Self-citation
Metadata
- Authors
- Nair, S., Branagan, A. R., Liu, J., Boddupalli, C. S., Mistry, P. K., & Dhodapkar, M. V.
- Affiliations
- Yale Cancer Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-02-11
- Volume
- 374
- Issue
- 6
- Pages
- 555-561
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4804194
- OpenAlex
- W2321709204
- Cited by
- 203
- References
- 26
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 11 · 2023: 22 · 2022: 27 · 2021: 17 · 2020: 26 · 2019: 22 · 2018: 23 · 2017: 17 · 2016: 14
- FWCI
- 24.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Public Health Service (NIAMS 65932)
- National Cancer Institute (R01CA135110, CA 106802, CA135110, R01CA156689, CA156689, R01CA106802, R35CA197603, P30CA016359)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034989)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR065932)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- multiple myeloma, Gaucher disease, lysolipids, lysophosphatidylcholine, antigen-driven selection, substrate reduction therapy, lipid metabolism, monoclonal gammopathy of undetermined significance, plasma cell dyscrasia
- MeSH terms
- Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Gaucher Disease, Glucosylceramides, Humans, Immunoglobulins, Lysophosphatidylcholines, Multiple Myeloma, Paraproteinemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
